ArticleNature genetics2015
Transposon mutagenesis identifies genetic drivers of Braf(V600E) melanoma.
Article in Nature genetics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 71 citations in OpenAlex.
- A forward genetic screen identifies Sirtuin1 as a driver of neuroendocrine prostate cancer.The Journal of experimental medicine · 2026Article
- RAD51B-EZH2 axis as a potential therapeutic target for TNBC through cell fate conversion.Cell death & disease · 2025Article
- Transcriptional reprogramming triggered by neonatal UV radiation or Lkb1 loss prevents BRAFOncogene · 2025Article
- Transposon mediated functional genomic screening for BRAF inhibitor resistance reveals convergent Hippo and MAPK pathway activation events.Scientific reports · 2025Article
- Rodent models of tumours of the central nervous system.Molecular oncology · 2024Review
- Explainable Multilayer Graph Neural Network for cancer gene prediction.Bioinformatics (Oxford, England) · 2023Article
- GREB1 isoform 4 is specifically transcribed by MITF and required for melanoma proliferation.Oncogene · 2023Article
- High-Throughput Identification, Modeling, and Analysis of Cancer Driver Genes In Vivo.Cold Spring Harbor perspectives in medicine · 2023Review
- Dynamic ctDNA Mutational Complexity in Patients with Melanoma Receiving Immunotherapy.Molecular diagnosis & therapy · 2023Observational
- SB Digestor: a tailored driver gene identification tool for dissecting heterogeneous Sleeping Beauty transposon-induced tumors.International journal of biological sciences · 2023Article
- Transposon Mutagenesis Reveals RBMS3 Silencing as a Promoter of Malignant Progression of BRAFV600E-Driven Lung Tumorigenesis.Cancer research · 2022Article
- Ring Finger Protein 125 Is an Anti-Proliferative Tumor Suppressor in Hepatocellular Carcinoma.Cancers · 2022Article
- Revealing the genetic basis of eyelid pigmentation in Hereford cattle.Journal of animal science · 2022Article
- UVB mutagenesis differs inLife science alliance · 2021Article
- Transposon mutagenesis identifies cooperating genetic drivers during keratinocyte transformation and cutaneous squamous cell carcinoma progression.PLoS genetics · 2021Article
- Identification of cancer driver genes using Sleeping Beauty transposon mutagenesis.Cancer science · 2021Review
- Melanoma models for the next generation of therapies.Cancer cell · 2021Review
- Teneurins: Role in Cancer and Potential Role as Diagnostic Biomarkers and Targets for Therapy.International journal of molecular sciences · 2021Review
- Promoterless Transposon Mutagenesis Drives Solid Cancers via Tumor Suppressor Inactivation.Cancers · 2021Article
- In vivo functional screening for systems-level integrative cancer genomics.Nature reviews. Cancer · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 8 institutions in 4 countries.
Funding
Abstract
Although nearly half of human melanomas harbor oncogenic BRAF(V600E) mutations, the genetic events that cooperate with these mutations to drive melanogenesis are still largely unknown. Here we show that Sleeping Beauty (SB) transposon-mediated mutagenesis drives melanoma progression in Braf(V600E) mutant mice and identify 1,232 recurrently mutated candidate cancer genes (CCGs) from 70 SB-driven melanomas. CCGs are enriched in Wnt, PI3K, MAPK and netrin signaling pathway components and are more highly connected to one another than predicted by chance, indicating that SB targets cooperative genetic networks in melanoma. Human orthologs of >500 CCGs are enriched for mutations in human melanoma or showed statistically significant clinical associations between RNA abundance and survival of patients with metastatic melanoma. We also functionally validate CEP350 as a new tumor-suppressor gene in human melanoma. SB mutagenesis has thus helped to catalog the cooperative molecular mechanisms driving BRAF(V600E) melanoma and discover new genes with potential clinical importance in human melanoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.